Palisade Bio (PALI) Current Deferred Revenue (2011)
Palisade Bio (PALI) reported Current Deferred Revenue of $52833.0 for Q3 2011.
Palisade Bio (PALI) Current Deferred Revenue (2011) Analysis & Trends
Palisade Bio (PALI) has 1 years of Current Deferred Revenue data on file, last reported at $52833.0 in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 52,833.00 |